AveXis Stock Price, News & Analysis (NASDAQ:AVXS)

$97.28 -1.48 (-1.50 %)
(As of 11/17/2017 02:16 PM ET)
Previous Close$97.28
Today's Range$98.59 - $95.68
52-Week Range$44.68 - $108.27
Volume290,996 shs
Average Volume435,255 shs
Market Capitalization$3.16 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A

About AveXis (NASDAQ:AVXS)

AveXis logoAveXis, Inc. is a clinical-stage gene therapy company. The Company operates through the developing and commercializing gene therapy treatments for patients suffering from neurological genetic diseases segment. The Company's product candidate, AVXS-101, is its gene therapy product candidate that is in a Phase I clinical trial for the treatment of spinal muscular atrophy (SMA) Type 1, which is a genetic disorder characterized by motor neuron loss and associated muscle deterioration. The survival motor neuron (SMN) is a protein for normal motor neuron signaling and function. Patients with SMA Type 1 either have experienced a deletion of their SMN1 genes, which prevents them from producing adequate levels of functional SMN protein, or carry a mutation in their SMN1 gene. AVXS-101 is designed to deliver a functional human SMN gene into the nuclei of motor neurons that then generates an increase in SMN protein levels.


Industry, Sector and Symbol:
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Sector: Bio Therapeutic Drugs
  • Symbol: NASDAQ:AVXS
  • CUSIP: N/A
  • Web: avexis.com
Debt:
  • Current Ratio: 13.96%
  • Quick Ratio: 13.96%
Sales & Book Value:
  • Annual Sales: N/A
  • Price / Sales: N/A
  • Book Value: $12.64 per share
  • Price / Book: 7.70
Profitability:
  • Trailing EPS: ($5.58)
  • Net Income: ($83,010,000.00)
  • Return on Equity: -49.27%
  • Return on Assets: -45.59%
Misc:
  • Employees: 70
  • Outstanding Shares: 31,980,000
 

Frequently Asked Questions for AveXis (NASDAQ:AVXS)

What is AveXis' stock symbol?

AveXis trades on the NASDAQ under the ticker symbol "AVXS."

How were AveXis' earnings last quarter?

AveXis, Inc. (NASDAQ:AVXS) issued its earnings results on Thursday, November, 9th. The company reported ($1.52) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.48) by $0.04. During the same period in the previous year, the company posted ($0.87) EPS. View AveXis' Earnings History.

Where is AveXis' stock going? Where will AveXis' stock price be in 2017?

16 equities research analysts have issued 12 month target prices for AveXis' shares. Their forecasts range from $52.00 to $134.00. On average, they expect AveXis' stock price to reach $109.88 in the next twelve months. View Analyst Ratings for AveXis.

What are Wall Street analysts saying about AveXis stock?

Here are some recent quotes from research analysts about AveXis stock:

  • 1. Chardan Capital analysts commented, "We also encourage investors consider the high proportion of Spinraza events/deaths (see Figure 2) that occurred within 6 months after treatment was started, causing investigators to say this result indicates that a minimum treatment time is required to see the full benefits of [Spinraza]", consistent with our thesis that Spinraza has an important limitation in that it takes considerably longer than AVXS-101 to achieve levels necessary for efficacy. As with other medical emergencies (e.g. MI, stroke), we expect that in SMA 1, the therapeutic agent that dominates the market is likely to be the one that provides efficacy within a reasonable time frame." (11/2/2017)
  • 2. According to Zacks Investment Research, "AveXis, Inc. is a gene therapy company which develops and commercializes treatments for neurological genetic diseases primarily in United States. The Company's product candidate consists of AVXS-101 which is in clinical trial for the treatment of spinal muscular atrophy Type 1, the genetic cause of infant mortality. AveXis, Inc. is headquartered in Bannockburn, Illinois. " (10/30/2017)
  • 3. Jefferies Group LLC analysts commented, "Final data from AVXS-101 in SMA T1 reported that all pts in both cohorts were event free at 13.6 mo of age compared to 25% expected via natural history, the primary EP. Motor milestones were achieved with 9 pts sitting ' 5 secs and 2 pts walking independently. We have lowered our EU T1 risk adj to 15% and began including SMA T2 into our valuation with a 75% risk adj. We reiterate our Buy rating and raise our PT to $92." (3/17/2017)
  • 4. The Goldman Sachs Group, Inc. analysts commented, "AVXS reported compelling gene therapy AVXS-101 Ph1 final results in spinal muscular atrophy (SMA, genetic neuromuscular disorder) Type I for all patients >13.6 months of age. The data continues to impress ' event-free survival (EFS, death or permanent ventilation) remains 100% in the 12 patients in the high dose therapeutic and notably, in the 3 non-therapeutic cohort as of 1/20. These results are remarkably better than the disease natural history of SMA Type I that suggests 25% EFS at 13.6 months. CHOP INTEND (motor function) and milestone improvements remain intact, with mean increase from baseline of +24.7 (vs. +24.8 prior) in the therapeutic dose vs. -10.5/yr per natural history. 11 (92%) patients are sitting unassisted (by definition, SMA Type I patients never sit unassisted), 9 (75%) rolling over, 2 (17%) standing alone and 2 (17%) walking independently, in line with prior 3m data. On the safety front, SAEs remain restricted to prior asymptomatic liver enzyme elevations which resolved with steroids. We look to: (1) the May 1 FDA meeting (vs. Mar) to discuss the manufacturing (CMC) outlook and June update post receipt of minutes; and (2) an end-of-Ph1 meeting with the FDA in 2Q/3Q to discuss a potential accelerated approval, which would provide upside to our estimates (we assume a 2020 launch on Ph3 data, GSe peak sales of $927mn)." (3/17/2017)

Who are some of AveXis' key competitors?

Who are AveXis' key executives?

AveXis' management team includes the folowing people:

  • Daniel G. Welch, Independent Chairman of the Board (Age 59)
  • Sean Patrick Nolan, President, Chief Executive Officer, Director (Age 49)
  • Phillip B. Donenberg, Principal Financial Officer, Senior Vice President, Principal Accounting Officer (Age 57)
  • Lori J. Smith, Chief Human Resource Officer, Senior Vice President (Age 53)
  • Michael Johannesen, Senior Vice President, Chief Compliance Officer, General Counsel (Age 51)
  • Andrew F. Knudten, Senior Vice President - Manufacturing and Supply Chain (Age 49)
  • James J. L'Italien Ph.D., Senior Vice President - Chief Regulatory and Quality Officer (Age 64)
  • Rick Modi, Senior Vice President, Chief Business Officer (Age 48)
  • Sukumar Nagendran, Senior Vice President and Chief Medical Officer (Age 50)
  • R. A. Session II, Senior Vice President - Corporate Strategy and Project Management (Age 38)

When did AveXis IPO?

(AVXS) raised $86 million in an initial public offering on Thursday, February 11th 2016. The company issued 4,300,000 shares at $19.00-$21.00 per share. Goldman Sachs and Jefferies acted as the underwriters for the IPO and BMO Capital Markets and Chardan were co-managers.

Who owns AveXis stock?

AveXis' stock is owned by many different of retail and institutional investors. Top institutional shareholders include FLYNN JAMES E (7.28%), Janus Henderson Group PLC (3.21%), Perceptive Advisors LLC (2.10%), Point72 Asset Management L.P. (2.01%), RTW Investments LP (1.46%) and Westfield Capital Management Co. LP (1.28%). Company insiders that own AveXis stock include Bong Y Koh, Brian K Kaspar, James E Flynn, Paul B Manning and Sukumar Nagendran. View Institutional Ownership Trends for AveXis.

Who sold AveXis stock? Who is selling AveXis stock?

AveXis' stock was sold by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., RTW Investments LP, Artal Group S.A., EAM Investors LLC, Russell Investments Group Ltd., Iguana Healthcare Management LLC, TD Asset Management Inc. and Ameriprise Financial Inc.. Company insiders that have sold AveXis company stock in the last year include Brian K Kaspar and Sukumar Nagendran. View Insider Buying and Selling for AveXis.

Who bought AveXis stock? Who is buying AveXis stock?

AveXis' stock was acquired by a variety of institutional investors in the last quarter, including Westfield Capital Management Co. LP, Perceptive Advisors LLC, Janus Henderson Group PLC, TimesSquare Capital Management LLC, Eagle Asset Management Inc., Nicholas Investment Partners LP, First Trust Advisors LP and Schwab Charles Investment Management Inc.. Company insiders that have bought AveXis stock in the last two years include Bong Y Koh and James E Flynn. View Insider Buying and Selling for AveXis.

How do I buy AveXis stock?

Shares of AveXis can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is AveXis' stock price today?

One share of AveXis stock can currently be purchased for approximately $97.28.

How big of a company is AveXis?

AveXis has a market capitalization of $3.16 billion. The company earns ($83,010,000.00) in net income (profit) each year or ($5.58) on an earnings per share basis. AveXis employs 70 workers across the globe.

How can I contact AveXis?

AveXis' mailing address is 2275 Half Day Rd Ste 160, BANNOCKBURN, IL 60015-1221, United States. The company can be reached via phone at +1-972-7257797 or via email at [email protected]


MarketBeat Community Rating for AveXis (NASDAQ AVXS)

Community Ranking:  3.3 out of 5 (star star star)
Outperform Votes:  188 (Vote Outperform)
Underperform Votes:  99 (Vote Underperform)
Total Votes:  287
MarketBeat's community ratings are surveys of what our community members think about AveXis and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for AveXis (NASDAQ:AVXS)

  (How are Consensus Ratings Calculated?)
Ratings Breakdown: 2 Sell Ratings, 2 Hold Ratings, 12 Buy Ratings, 0 Strong Buy Ratings
Consensus Rating:Buy (Score: 2.63)
Consensus Price Target: $109.88 (12.95% upside)

Consensus Price Target History for AveXis (NASDAQ:AVXS)

Price Target History for AveXis (NASDAQ:AVXS)

Analysts' Ratings History for AveXis (NASDAQ:AVXS)

Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
11/10/2017Bank of America CorporationLower Price TargetBuy$115.00 -> $112.00N/AView Rating Details
11/10/2017Royal Bank Of CanadaBoost Price TargetSector Perform -> Sector Perform$92.00 -> $97.00N/AView Rating Details
11/2/2017Chardan CapitalReiterated RatingBuyN/AView Rating Details
10/26/2017Canaccord GenuityInitiated CoverageHold -> Hold$110.00N/AView Rating Details
10/12/2017BMO Capital MarketsReiterated RatingOutperform$123.00 -> $130.00N/AView Rating Details
10/12/2017Jefferies Group LLCBoost Price TargetBuy$118.00N/AView Rating Details
10/6/2017The Goldman Sachs Group, Inc.Reiterated RatingBuy -> Buy$130.00N/AView Rating Details
10/2/2017Citigroup Inc.Boost Price TargetBuy$100.00 -> $116.00LowView Rating Details
9/29/2017Wells Fargo & CompanyReiterated RatingOutperformHighView Rating Details
9/6/2017Barclays PLCInitiated CoverageOverweight$124.00LowView Rating Details
8/29/2017InstinetInitiated CoverageReduce -> Reduce$52.00LowView Rating Details
8/28/2017NomuraInitiated CoverageReduce$52.00HighView Rating Details
8/23/2017William BlairInitiated CoverageOutperform -> Outperform$107.00MediumView Rating Details
8/16/2017Evercore ISIInitiated CoverageOutperform -> Outperform$120.00MediumView Rating Details
8/9/2017Morgan StanleyReiterated RatingOverweight$118.00LowView Rating Details
7/27/2017Sanford C. BernsteinInitiated CoverageOutperform$108.00MediumView Rating Details
11/14/2016Stifel NicolausInitiated CoverageHold$65.00N/AView Rating Details
(Data available from 11/18/2015 forward)

Earnings

Earnings History and Estimates Chart for AveXis (NASDAQ:AVXS)

Earnings by Quarter for AveXis (NASDAQ:AVXS)

Earnings History by Quarter for AveXis (NASDAQ AVXS)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/9/2017Q3 2017($1.48)($1.52)ViewN/AView Earnings Details
8/10/2017Q2 2017($0.97)($2.07)ViewN/AView Earnings Details
5/11/2017Q1 2017($0.95)($1.07)ViewN/AView Earnings Details
3/16/2017Q4 2016($0.77)($0.92)ViewN/AView Earnings Details
11/10/2016Q3 2016($0.70)($0.87)ViewListenView Earnings Details
8/11/2016Q216($0.77)($0.68)ViewListenView Earnings Details
5/12/2016Q1($0.35)($1.24)ViewListenView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for AveXis (NASDAQ:AVXS)
2017 EPS Consensus Estimate: ($2.74)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q3 20171($1.35)($1.35)($1.35)
Q4 20171($1.39)($1.39)($1.39)
Q3 20181($1.58)($1.58)($1.58)
Q4 20181($0.96)($0.96)($0.96)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for AveXis (NASDAQ:AVXS)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for AveXis (NASDAQ AVXS)

Insider Ownership Percentage: 18.60%
Institutional Ownership Percentage: 94.96%
Insider Trades by Quarter for AveXis (NASDAQ:AVXS)
Insider Trades by Quarter for AveXis (NASDAQ:AVXS)

Insider Trades by Quarter for AveXis (NASDAQ AVXS)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/1/2017Brian K KasparInsiderSell15,000$101.23$1,518,450.00View SEC Filing  
11/1/2017Sukumar NagendranVPSell1,780$101.26$180,242.80View SEC Filing  
10/9/2017Brian K KasparInsiderSell15,000$101.46$1,521,900.00View SEC Filing  
10/2/2017Sukumar NagendranVPSell1,780$97.25$173,105.00View SEC Filing  
9/1/2017Sukumar NagendranVPSell1,780$93.25$165,985.00View SEC Filing  
8/1/2017Sukumar NagendranVPSell1,780$91.52$162,905.60View SEC Filing  
7/3/2017Sukumar NagendranVPSell1,780$81.88$145,746.40View SEC Filing  
6/1/2017Sukumar NagendranVPSell1,780$70.91$126,219.80View SEC Filing  
5/1/2017Sukumar NagendranVPSell1,780$81.39$144,874.20View SEC Filing  
4/3/2017Sukumar NagendranVPSell1,781$76.13$135,587.53View SEC Filing  
9/13/2016Paul B ManningInsiderSell289,855$34.50$9,999,997.50View SEC Filing  
2/17/2016Bong Y KohDirectorBuy100,000$20.00$2,000,000.00View SEC Filing  
2/17/2016James E FlynnInsiderBuy750,317$19.47$14,608,671.99View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for AveXis (NASDAQ:AVXS)

Latest Headlines for AveXis (NASDAQ AVXS)

Source:
DateHeadline
AveXis, Inc. (AVXS) Expected to Post Earnings of -$1.51 Per ShareAveXis, Inc. (AVXS) Expected to Post Earnings of -$1.51 Per Share
www.americanbankingnews.com - November 18 at 9:16 AM
Comparing AveXis (AVXS) & Dyax Corp. (DYAX)Comparing AveXis (AVXS) & Dyax Corp. (DYAX)
www.americanbankingnews.com - November 17 at 5:22 AM
AveXis, Inc. (AVXS) Forecasted to Post Q3 2018 Earnings of ($1.58) Per ShareAveXis, Inc. (AVXS) Forecasted to Post Q3 2018 Earnings of ($1.58) Per Share
www.americanbankingnews.com - November 13 at 7:54 AM
Royal Bank Of Canada Boosts AveXis, Inc. (AVXS) Price Target to $97.00Royal Bank Of Canada Boosts AveXis, Inc. (AVXS) Price Target to $97.00
www.americanbankingnews.com - November 12 at 1:10 PM
AveXis, Inc. (AVXS) Price Target Lowered to $112.00 at Bank of America CorporationAveXis, Inc. (AVXS) Price Target Lowered to $112.00 at Bank of America Corporation
www.americanbankingnews.com - November 11 at 8:24 PM
Edited Transcript of AVXS earnings conference call or presentation 9-Nov-17 9:30pm GMTEdited Transcript of AVXS earnings conference call or presentation 9-Nov-17 9:30pm GMT
finance.yahoo.com - November 10 at 1:13 PM
AveXis, Inc. (AVXS) Announces  Earnings ResultsAveXis, Inc. (AVXS) Announces Earnings Results
www.americanbankingnews.com - November 10 at 12:32 AM
After-Hours Earnings Report for November 9, 2017 : DIS, NVDA, JWN, MSCC, NWSA, AL, PBYI, ICUI, AVXS, LGND ... - NasdaqAfter-Hours Earnings Report for November 9, 2017 : DIS, NVDA, JWN, MSCC, NWSA, AL, PBYI, ICUI, AVXS, LGND ... - Nasdaq
www.nasdaq.com - November 9 at 5:29 PM
AveXis Reports Third Quarter 2017 Financial and Operating ResultsAveXis Reports Third Quarter 2017 Financial and Operating Results
finance.yahoo.com - November 9 at 5:29 PM
AveXis Reports Third Quarter 2017 Financial and Operating Results - GlobeNewswire (press release)AveXis Reports Third Quarter 2017 Financial and Operating Results - GlobeNewswire (press release)
globenewswire.com - November 9 at 5:29 PM
Puma Biotechnology Flops Despite Topping Sales, Loss ExpectationsPuma Biotechnology Flops Despite Topping Sales, Loss Expectations
finance.yahoo.com - November 9 at 5:29 PM
REGENXBIO Reports Third Quarter 2017 Financial Results And Recent Operational HighlightsREGENXBIO Reports Third Quarter 2017 Financial Results And Recent Operational Highlights
www.thestreet.com - November 8 at 6:40 PM
Does AveXis Inc’s (AVXS) CEO Salary Compared Well With Others?Does AveXis Inc’s (AVXS) CEO Salary Compared Well With Others?
finance.yahoo.com - November 8 at 6:40 PM
Sukumar Nagendran Sells 1,780 Shares of AveXis, Inc. (AVXS) StockSukumar Nagendran Sells 1,780 Shares of AveXis, Inc. (AVXS) Stock
www.americanbankingnews.com - November 3 at 6:30 PM
AveXis, Inc. (AVXS) Insider Sells $1,518,450.00 in StockAveXis, Inc. (AVXS) Insider Sells $1,518,450.00 in Stock
www.americanbankingnews.com - November 3 at 5:25 PM
AveXis to Report Third Quarter 2017 Financial and Operating ResultsAveXis to Report Third Quarter 2017 Financial and Operating Results
finance.yahoo.com - November 2 at 4:48 PM
AveXis, Inc. (AVXS) Earns "Hold" Rating from Royal Bank Of CanadaAveXis, Inc. (AVXS) Earns "Hold" Rating from Royal Bank Of Canada
www.americanbankingnews.com - November 2 at 3:20 PM
AveXis Announces New England Journal of Medicine Publication of Phase 1 Data of AVXS-101 Gene Replacement ... - Business Wire (press release)AveXis Announces New England Journal of Medicine Publication of Phase 1 Data of AVXS-101 Gene Replacement ... - Business Wire (press release)
www.businesswire.com - November 1 at 9:55 PM
AveXis Announces New England Journal of Medicine Publication of Phase 1 Data of AVXS-101 Gene Replacement Therapy in Spinal Muscular Atrophy Type 1AveXis Announces New England Journal of Medicine Publication of Phase 1 Data of AVXS-101 Gene Replacement Therapy in Spinal Muscular Atrophy Type 1
finance.yahoo.com - November 1 at 9:54 PM
[$$] As Experimental Treatments Grow, Families Face Tough Choices[$$] As Experimental Treatments Grow, Families Face Tough Choices
finance.yahoo.com - November 1 at 9:54 PM
AveXis, Inc. (AVXS) Scheduled to Post Quarterly Earnings on WednesdayAveXis, Inc. (AVXS) Scheduled to Post Quarterly Earnings on Wednesday
www.americanbankingnews.com - November 1 at 4:06 AM
AveXis, Inc. (AVXS) Downgraded by Zacks Investment ResearchAveXis, Inc. (AVXS) Downgraded by Zacks Investment Research
www.americanbankingnews.com - October 30 at 4:36 PM
Biogen: Lets Start All Over AgainBiogen: Let's Start All Over Again
finance.yahoo.com - October 25 at 5:33 PM
AveXis (AVXS) vs. The Competition Head-To-Head SurveyAveXis (AVXS) vs. The Competition Head-To-Head Survey
www.americanbankingnews.com - October 25 at 3:42 PM
AveXis, Inc. (AVXS) Receives Consensus Recommendation of "Buy" from AnalystsAveXis, Inc. (AVXS) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - October 25 at 2:54 PM
AveXis, Inc. (AVXS) Lifted to Buy at Zacks Investment ResearchAveXis, Inc. (AVXS) Lifted to Buy at Zacks Investment Research
www.americanbankingnews.com - October 24 at 5:28 PM
3 Gene Therapy Stocks That Could Make You Rich - Motley Fool3 Gene Therapy Stocks That Could Make You Rich - Motley Fool
www.fool.com - October 23 at 9:18 PM
FY2018 EPS Estimates for AveXis, Inc. Lifted by Jefferies Group (AVXS)FY2018 EPS Estimates for AveXis, Inc. Lifted by Jefferies Group (AVXS)
www.americanbankingnews.com - October 16 at 7:56 AM
AveXis, Inc. (AVXS) Given New $118.00 Price Target at Jefferies Group LLCAveXis, Inc. (AVXS) Given New $118.00 Price Target at Jefferies Group LLC
www.americanbankingnews.com - October 15 at 8:54 AM
BMO Capital Markets Reaffirms "Outperform" Rating for AveXis, Inc. (AVXS)BMO Capital Markets Reaffirms "Outperform" Rating for AveXis, Inc. (AVXS)
www.americanbankingnews.com - October 12 at 9:46 AM
AveXis, Inc. (AVXS) Insider Sells $1,521,900.00 in StockAveXis, Inc. (AVXS) Insider Sells $1,521,900.00 in Stock
www.americanbankingnews.com - October 11 at 7:30 PM
Short Interest Decreases By 16.8% For AVXSShort Interest Decreases By 16.8% For AVXS
www.thestreet.com - October 11 at 5:48 PM
Goldman Sachs Group, Inc. (The) Reiterates Buy Rating for AveXis, Inc. (AVXS)Goldman Sachs Group, Inc. (The) Reiterates Buy Rating for AveXis, Inc. (AVXS)
www.americanbankingnews.com - October 7 at 12:58 AM
BRIEF-AveXis to report top-line data from phase 1 clinical trial of AVXS-101BRIEF-AveXis to report top-line data from phase 1 clinical trial of AVXS-101
www.reuters.com - October 3 at 3:58 PM
Featured Company News - AveXis Intends To Initiate Pivotal Trial Of AVXS-101 In SMA Type 1 On An Immediate BasisFeatured Company News - AveXis Intends To Initiate Pivotal Trial Of AVXS-101 In SMA Type 1 On An Immediate Basis
finance.yahoo.com - October 3 at 3:58 PM
AveXis to Report Top-line Data from the Phase 1 Clinical Trial of AVXS-101 in SMA Type 1 at the International Annual Congress of the World Muscle SocietyAveXis to Report Top-line Data from the Phase 1 Clinical Trial of AVXS-101 in SMA Type 1 at the International Annual Congress of the World Muscle Society
finance.yahoo.com - October 3 at 3:58 PM
AveXis Flies, But PTC Sinks On Spinal Muscular Atrophy DataAveXis Flies, But PTC Sinks On Spinal Muscular Atrophy Data
finance.yahoo.com - October 3 at 3:58 PM
AveXis (AVXS) Buy Rating Reaffirmed at UBS AGAveXis' (AVXS) Buy Rating Reaffirmed at UBS AG
www.americanbankingnews.com - October 3 at 8:41 AM
[$$] Gene Therapy Is Nearing a Major Breakthrough[$$] Gene Therapy Is Nearing a Major Breakthrough
finance.yahoo.com - October 2 at 4:08 PM
AveXis Announces Plan to Initiate Pivotal Trial of AVXS-101 in SMA Type 1 Using Product from New GMP Commercial ProcessAveXis Announces Plan to Initiate Pivotal Trial of AVXS-101 in SMA Type 1 Using Product from New GMP Commercial Process
finance.yahoo.com - October 2 at 4:08 PM
AveXis: Now Thats a Go Ahead!AveXis: Now That's a Go Ahead!
finance.yahoo.com - October 2 at 4:08 PM
AveXis Announces Plan to Initiate Pivotal Trial of AVXS-101 in SMA Type 1 Using Product from New GMP Commercial ... - GlobeNewswire (press release)AveXis Announces Plan to Initiate Pivotal Trial of AVXS-101 in SMA Type 1 Using Product from New GMP Commercial ... - GlobeNewswire (press release)
globenewswire.com - September 30 at 11:55 PM
BRIEF-Avexis to initiate pivotal trial of AVXS-101 in SMA type 1BRIEF-Avexis to initiate pivotal trial of AVXS-101 in SMA type 1
www.reuters.com - September 30 at 1:51 PM
BMO Capital Markets Reiterates Outperform Rating for AveXis, Inc. (AVXS)BMO Capital Markets Reiterates Outperform Rating for AveXis, Inc. (AVXS)
www.americanbankingnews.com - September 30 at 1:10 PM
AveXis, Inc. (AVXS) Receives Average Rating of "Buy" from AnalystsAveXis, Inc. (AVXS) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - September 30 at 12:44 PM
AveXis, Inc. (AVXS) Earns "Outperform" Rating from Wells Fargo & CompanyAveXis, Inc. (AVXS) Earns "Outperform" Rating from Wells Fargo & Company
www.americanbankingnews.com - September 29 at 1:31 PM
Royal Bank Of Canada Begins Coverage on AveXis, Inc. (AVXS)Royal Bank Of Canada Begins Coverage on AveXis, Inc. (AVXS)
www.americanbankingnews.com - September 14 at 11:06 PM
Notable Thursday Option Activity: NFLX, AVXS, ICPTNotable Thursday Option Activity: NFLX, AVXS, ICPT
www.nasdaq.com - September 14 at 4:51 PM
Breaking Down Barclays New Bullish Calls On BiotechBreaking Down Barclays' New Bullish Calls On Biotech
finance.yahoo.com - September 7 at 9:19 PM
AveXis, Inc. (AVXS) Coverage Initiated at Barclays PLCAveXis, Inc. (AVXS) Coverage Initiated at Barclays PLC
www.americanbankingnews.com - September 6 at 5:18 PM

Social Media

Financials

Chart

AveXis (NASDAQ AVXS) Chart for Saturday, November, 18, 2017
Loading chart…

This page was last updated on 11/18/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.